MedTrace Logo

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

NCT05490472 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2026-01-09

No results posted yet for this study

Summary

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Conditions

  • Solid Tumors
  • ER+ Breast Cancer
  • Triple Negative Breast Cancer, TNBC
  • ARID1A Gene Mutation
  • Small Cell Lung Cancer, SCLC

Interventions

DRUG

JAB-2485 (Aurora A inhibitor)

Administered orally

DRUG

JAB-2485 (Aurora A inhibitor)

Administered orally

Sponsors & Collaborators

  • Jacobio Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2026-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05490472 on ClinicalTrials.gov